BREAST CANCER

The FDA has granted approval to pembrolizumab for the treatment of patients with high-risk early-stage triple-negative breast cancer in combination with chemotherapy as neoadjuvant treatment and then continued as a single agent as adjuvant treatment after surgery.

The combination of the ant-PD-1 inhibitor, pembrolizumab plus chemotherapy before surgery continued by pembrolizumab as a single agent led to statistically significant event-free survival result versus neoadjuvant chemotherapy alone in patients with high-risk early-stage triple-negative breast cancer.

Regardless of age the combination of ribociclib and endocrine therapy led to improved overall survival in pre- or postmenopausal patients with hormone receptor-positive, HER2-negative advanced breast cancer.

Encouraging findings from theTROPION-PanTumor01 trial revealed a positive response and safety profile for the antibody-drug conjugate datopotamab deruxtecan in patients with triple-negative breast cancer.

Treatment with atezolizumab plus carboplatin demonstrated early clinical activity in patients with metastatic invasive lobular breast cancer, with slight trends toward increased clinical benefit in patients with triple-negative ILC and responders with higher PD-L1 expression.

An expert in breast oncology shares her thoughts on the importance of the AMEERA-5 findings to the evolving treatment landscape for HR+ breast cancer.

Sara Hurvitz, MD, reviews clinical trial data on amcenestrant, an orally administered endocrine therapy, in patients with ER+/HER2- breast cancer as shown in the AMEERA trials.

Sara Hurvitz, MD, discusses the therapeutic landscape for HR+ advanced breast cancer and considerations for treatment selection.

Sara Hurvitz, MD, provides an overview of HR+ breast cancer.

Balixafortide in combination with eribulin did not improve objective response rate compared to eribulin alone for the treatment of HER2-negative, locally recurrent or metastatic breast cancer, missing the coprimary end point of the FORTRESS study.

Hope Rugo, MD, provides insights on best practices for managing metastatic TNBC in community settings.

An expert explains the different types of immune-related adverse effects associated with the use of immune checkpoint inhibitors.

Dr Hope Rugo discusses the importance of testing for germline BRCA1/2 mutations in patients with triple-negative breast cancer.

Hope Rugo, MD, continues to discuss key clinical trials affecting metastatic triple-negative breast cancer, including IMpassion131.

An expert in breast oncology discusses the IMpassion130 and KEYNOTE-355 clinical trials.

Dr Rugo educates on early stage treatment options and molecular testing guidelines for patients with metastatic triple-negative breast cancer.

Hope Rugo, MD, discusses the case of a 49-year-old woman diagnosed with metastatic triple-negative breast cancer.

An FDA Oncologic Drugs Advisory Committee meeting resulted in continued approval for 4 of 6 indications that were discussed, although all 6 indications did not demonstrate clinical benefit in confirmatory studies. The meeting, held April 27-29, evaluated anti–PD-1/PD-L1 drugs that received accelerated approvals through the FDA’s accelerated approval program, a nearly 30-year-old initiative to expedite the approval process.

Treatment with [vic-]trastuzumab duocarmazine (SYD985) demonstrated a statistically significant improvement in progression-free survival compared with physician’s choice of treatment in patients with pretreated HER2-positive unresectable locally advanced or metastatic breast cancer, meeting the primary end point of the phase 3 TULIP study, according to a press release from Byondis B.V.

The panel of experts in breast cancer discuss enrollment of patients with TNBC in clinical trials, including considerations and barriers.

Experts in the field of breast cancer review the role of genetic testing in the selection of treatment for patients with TNBC.

Ruta Rao, MD, discusses practical considerations regarding the use of sacituzumab govitecan in patients with relapsed/refractory TNBC.

The panel of experts share their treatment recommendations for patients with residual disease after an incomplete response to TNBC therapy.

Pathologist David G. Hicks, MD, discusses the impact of residual disease in breast cancer treatment outcomes.

Elizabeth Mittendorf, MD, PhD, and Ruta Rao, MD, present the case of a 48-year-old woman with stage T2N1 TNBC.